| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg |
| Targets |
The molecular target of Gypenoside XLVI has not been fully characterized. As a dammarane-type saponin, it is believed to exert its effects through modulation of cell signaling pathways involved in proliferation and apoptosis. Its potent inhibitory activity against A549 lung cancer cells suggests interaction with pathways critical for cancer cell survival.
|
|---|---|
| ln Vitro |
In vitro, Gypenoside XLVI shows strong cytotoxic activity against A549 human lung carcinoma cells, with an IC₅₀ value of 52.63 ± 8.31 μg/mL. It induces apoptosis in A549 cells. As a major dammarane-type saponin from Gynostemma pentaphyllum, it demonstrates potent non-small cell lung carcinoma cell inhibitory activity.
|
| ln Vivo |
In vivo activity data for Gypenoside XLVI are limited in the available literature. As a natural product research compound, its primary application is in in vitro cancer studies. The compound's potent activity against A549 cells suggests potential for in vivo anti-tumor efficacy, but systematic in vivo studies have not been extensively reported.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Gypenoside XLVI are not extensively documented. As a natural saponin, its biological activity is typically assessed in cell-based assays rather than cell-free enzyme assays. The compound's ability to inhibit cancer cell proliferation is measured using standard cytotoxicity assays such as MTT or CCK-8.
|
| Cell Assay |
In vitro cellular assays for Gypenoside XLVI are performed using A549 human lung carcinoma cells. Cells are treated with increasing concentrations of the compound, and cell viability is assessed using colorimetric assays such as MTT or CCK-8. The IC₅₀ value (52.63 ± 8.31 μg/mL) is calculated from the dose-response curve. Apoptosis is evaluated by measuring markers of programmed cell death.
|
| Animal Protocol |
In vivo animal experimental protocols for Gypenoside XLVI are not extensively documented. As a natural product research compound, in vivo studies would typically involve administration to mouse xenograft models bearing A549 tumors. The compound would be administered via oral or intraperitoneal routes, and efficacy would be assessed by measuring tumor volume reduction and body weight changes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Gypenoside XLVI have not been systematically characterized. The compound has a molecular weight of 963.15 and molecular formula C₄₈H₈₂O₁₉. It is a dammarane-type triterpenoid saponin with high purity (97-99.69%). The compound is isolated from Gynostemma pentaphyllum and is soluble in DMSO. Further PK studies are needed to determine its bioavailability and metabolic profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Gypenoside XLVI are not extensively reported. As a research-use natural product, its safety profile has not been formally evaluated in comprehensive toxicology studies. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Gynostemma pentaphyllum has been reported to contain gypenosin XLVI, and relevant data are available for reference.
Gypenoside XLVI is a dammarane-type triterpenoid saponin with CAS number 94705-70-1, molecular formula C₄₈H₈₂O₁₉, and molecular weight 963.15. It is isolated from Gynostemma pentaphyllum. It exhibits potent inhibitory activity against A549 human lung carcinoma cells with an IC₅₀ of 52.63 ± 8.31 μg/mL. This product is for research use only. |
| Molecular Formula |
C48H82O19
|
|---|---|
| Molecular Weight |
963.153297901154
|
| Exact Mass |
962.545
|
| CAS # |
94705-70-1
|
| PubChem CID |
75090527
|
| Appearance |
White to light yellow solid powder
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1CC2C3(C)CC(C(C(C)(C)C3CCC2(C)C2(C)CCC(C(C)(CC/C=C(\C)/C)OC3C(C(C(C(CO)O3)O)O)O)C21)OC1C(C(C(C(CO)O1)O)O)OC1C(C(C(C(CO)O1)O)O)O)O
|
| InChi Key |
VENRSYBHHVDBDC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)63-42)22-11-14-47(7)30(22)23(52)16-29-45(5)17-24(53)40(44(3,4)28(45)12-15-46(29,47)6)66-43-39(36(59)33(56)27(20-51)64-43)65-41-37(60)34(57)31(54)25(18-49)62-41/h10,22-43,49-61H,9,11-20H2,1-8H3
|
| Chemical Name |
2-[2-[[2,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[6-methyl-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~103.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
